Clinical commentary: Medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer?

Gynecologic oncology

Volumn 134, Issue 3, 2014, Pages 447-449

  Krill, Lauren S ^a   Adelson, Joel W ^a   Randall, Leslie M ^a   Bristow, Robert E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BOLDENONE UNDECENOATE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; TESTOSTERONE;

ARTICLE; BIOETHICS; CLINICAL TRIAL (TOPIC); ETHICS; FEMALE; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOETHICAL ISSUES; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; ETHICS, MEDICAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; TESTOSTERONE; UTERINE CERVICAL NEOPLASMS;

EID: 84908311912     PISSN: None     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.06.017     Document Type: Editorial

References (0)